Alterity Therapeutics (ATHE) EPS (Weighted Average and Diluted) (2016 - 2020)

Alterity Therapeutics' EPS (Weighted Average and Diluted) history runs 5 years deep, the most recent figure standing at $13.17 for Q4 2020.

• In Q4 2020, EPS (Weighted Average and Diluted) rose 251.8% year-over-year to $13.17; the TTM figure through Jun 2022 stood at $0.0 (down 22.23% YoY), while the FY2025 annual figure was -$0.12, up 64.49% from the prior year.
• EPS (Weighted Average and Diluted) was $13.17 for Q4 2020 at Alterity Therapeutics, up from $0.01 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $13.17 in Q4 2020 to a low of -$8.68 in Q4 2019.
• Historically, EPS (Weighted Average and Diluted) has averaged -$0.67 across 5 years, with a median of -$2.54 in 2017.
• The sharpest annual moves came in 2019 and 2020: EPS (Weighted Average and Diluted) plunged 151.86% in 2019, then surged 251.8% in 2020.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$2.52 in 2016, then declined by 1.87% to -$2.57 in 2017, then slumped by 34.29% to -$3.45 in 2018, then slumped by 151.86% to -$8.68 in 2019, then soared by 251.8% to $13.17 in 2020.
• The last three EPS (Weighted Average and Diluted) figures came in at $13.17 (Q4 2020), $0.01 (Q2 2020), and -$8.68 (Q4 2019), per Business Quant data.